DAB2IP and breast carcinoma: Recent observations confirmed that DAB2IP is downregulated by promoter methylation in luminal B breast cancers [19], and that CpG methylation is inversely correlated with overall survival of patients with renal cell carcinoma, suggesting DAB2IP methylation as a prognostic indicator for this type of cancer [55].